tradingkey.logo

Dexcom Inc

DXCM
查看详细走势图
66.060USD
+0.150+0.23%
收盘 12/19, 16:00美东报价延迟15分钟
25.76B总市值
35.86市盈率 TTM

Dexcom Inc

66.060
+0.150+0.23%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+0.23%

5天

-1.34%

1月

+10.60%

6月

-18.45%

今年开始到现在

-15.06%

1年

-12.87%

查看详细走势图

TradingKey Dexcom Inc股票评分

单位: USD 更新时间: 2025-12-19

操作建议

Dexcom Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名28/208位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价86.34。中期看,股价处于平稳状态。近一个月,市场表现较强,技术面和基本面综合得分较高,较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

Dexcom Inc评分

相关信息

行业排名
28 / 208
全市场排名
97 / 4582
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 31 位分析师
买入
评级
86.336
目标均价
+31.57%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Dexcom Inc亮点

亮点风险
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
业绩高增长
公司营业收入稳步增长,连续3年增长38.60%
利润高增长
公司净利润处于行业前列,最新年度总收入4.03B美元
估值低估
公司最新PE估值35.86,处于3年历史低位
机构加仓
最新机构持股388.08M股,环比增加0.05%
ETHSX持仓
明星投资者ETHSX持仓,最新持仓市值103.84K

Dexcom Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Dexcom Inc简介

DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
公司代码DXCM
公司Dexcom Inc
CEOMr. Jacob Steven (Jake) Leach
网址https://www.dexcom.com/

常见问题

Dexcom Inc(DXCM)的当前股价是多少?

Dexcom Inc(DXCM)的当前股价是 66.060。

Dexcom Inc的股票代码是什么?

Dexcom Inc的股票代码是DXCM。

Dexcom Inc股票的52周最高点是多少?

Dexcom Inc股票的52周最高点是93.250。

Dexcom Inc股票的52周最低点是多少?

Dexcom Inc股票的52周最低点是54.110。

Dexcom Inc的市值是多少?

Dexcom Inc的市值是25.76B。

Dexcom Inc的净利润是多少?

Dexcom Inc的净利润为576.20M。

现在Dexcom Inc(DXCM)的股票是买入、持有还是卖出?

根据分析师评级,Dexcom Inc(DXCM)的总体评级为买入,目标价格为86.336。

Dexcom Inc(DXCM)股票的每股收益(EPS TTM)是多少

Dexcom Inc(DXCM)股票的每股收益(EPS TTM)是1.842。
KeyAI